Linezolid
- Generic Name
- Linezolid
- Brand Names
- Zyvox, Zyvoxam
- Drug Type
- Small Molecule
- Chemical Formula
- C16H20FN3O4
- CAS Number
- 165800-03-3
- Unique Ingredient Identifier
- ISQ9I6J12J
- Background
Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - ...
- Indication
Linezolid is indicated in adults and children for the treatment of infections caused by susceptible Gram-positive bacteria, including nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, and vancomycin-resistant Enterococcus faecium infections. Examples of susceptible bacteria include Staphylococcus aureus, Streptococcus pn...
- Associated Conditions
- Community Acquired Pneumonia (CAP) caused by Staphylococcus Aureus Infections, Community acquired pneumonia caused by Susceptible strains of Streptococcus pneumoniae, Complicated Skin and Skin Structure Infection caused by Staphylococcus Aureus Infections, Complicated Skin and Skin Structure Infection caused by Streptococcus Agalactiae Infection, Complicated Skin and Skin Structure Infection caused by Streptococcus Pyogenes Infection, Nosocomial Pneumonia caused by Staphylococcus Aureus Infections, Nosocomial Pneumonia caused by Streptococcus Pneumoniae Infections, Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus Aureus Infections, Uncomplicated Skin and Skin Structure Infections caused by Streptococcus Pyogenes Infection, Vancomycin-resistant Enterococcus faecium infection
- Associated Therapies
- -
Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin
- Conditions
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Boston University
- Registration Number
- NCT02975570
Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
- Conditions
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 735
- Registration Number
- NCT02877927
- Locations
- 🇺🇸
Site 620, Birmingham, Alabama, United States
🇺🇸Site 606, Buena Park, California, United States
🇺🇸Site 604, Chula Vista, California, United States
Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Fondation Hôpital Saint-Joseph
- Target Recruit Count
- 31
- Registration Number
- NCT02778828
- Locations
- 🇫🇷
Sanatorium du Petit Fontainebleau Centre Médical de Bligny, Briis-sous-Forges, Essonne, France
Evaluating Newly Approved Drugs for Multidrug-resistant TB
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Médecins Sans Frontières, France
- Target Recruit Count
- 754
- Registration Number
- NCT02754765
- Locations
- 🇵🇪
Hospital Nacional Dos de Mayo Parque Historia de la Medicina, Lima, Peru
🇰🇿National Center for Tuberculosis Problems, Almaty, Kazakhstan
🇬🇪National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 2
- Registration Number
- NCT02732327
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 860
- Registration Number
- NCT02679573
- Locations
- 🇺🇦
Melinta 306 Study Site, Zhytomyr, Ukraine
Treatment Shortening of MDR-TB Using Existing and New Drugs
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 238
- Registration Number
- NCT02619994
- Locations
- 🇰🇷
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of
AbioKin - Antibiotic Kinetics
- Conditions
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2021-01-19
- Target Recruit Count
- 1500
- Registration Number
- NCT02609646
- Locations
- 🇮🇹
Ospedale S. Giovanni di Dio ASL 10, Servizio Anestesia e Rianimazione, Firenze, FI, Italy
🇮🇹Ospedale San Giovanni di Dio, Orbetello, Grosseto, Italy
🇮🇹Ospedale A. Manzoni, U.O. Anestesia e Rianimazione 1, Lecco, Lombardia, Italy
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
- Conditions
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Medecins Sans Frontieres, Netherlands
- Target Recruit Count
- 552
- Registration Number
- NCT02589782
- Locations
- 🇿🇦
King DinuZulu Hospital, Durban, KwaZulu-Natal, South Africa
🇺🇿Republican TB Hospital No. 2, Nukus, Karakalpakstan, Uzbekistan
🇧🇾Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital, Minsk, Belarus
Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
- Conditions
- Interventions
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Arrevus Inc.
- Target Recruit Count
- 716
- Registration Number
- NCT02570490
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.